Xspray Pharma AB Sustainability Reports
Xspray Pharma AB develops improved, amorphous versions of established protein kinase inhibitors primarily targeted for cancer treatment. The company utilizes its proprietary HyNap technology platform to overcome solubility and secondary patent barriers of crystalline drugs.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300NGRQCNZ3X4L157
FIGI: BBG006N4HJL9
8 reports from 2018 to 2025